Who are Cotadutide 100 micrograms's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CagriSema.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cotadutide-100-micrograms.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Cotadutide 100 micrograms — Competitive Intelligence Brief

Cotadutide 100 micrograms (Cotadutide 100 micrograms) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual GLP-1/glucagon receptor agonist. Area: Diabetes, Obesity.

phase 2 Dual GLP-1/glucagon receptor agonist GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR) Diabetes, Obesity Small molecule Live · refreshed every 30 min

Target snapshot

Cotadutide 100 micrograms (Cotadutide 100 micrograms) — AstraZeneca. Cotadutide is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glucose control and promote weight loss.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cotadutide 100 micrograms TARGET	Cotadutide 100 micrograms	AstraZeneca	phase 2	Dual GLP-1/glucagon receptor agonist	GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR)
CagriSema	CagriSema	Novo Nordisk A/S	phase 3	Dual GLP-1/glucagon receptor agonist	GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual GLP-1/glucagon receptor agonist class)

AstraZeneca · 1 drug in this class
Novo Nordisk A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cotadutide 100 micrograms — Competitive Intelligence Brief. https://druglandscape.com/ci/cotadutide-100-micrograms. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab